araag2/HINT huggingface dataset:
Clinical trial NCT01604278 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: nva237 50 µg and indacaterol 150 µg, placebo to nva237 and indacaterol 150 µg
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage
             II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease
             (GOLD) Guidelines.

          -  Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30 %
             and/or <80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital
             Capacity (FVC) < 0.70 at screening.

          -  Current or ex-smokers who have a smoking history of at least 10 pack years

          -  Symptomatic patients according to daily diary data.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential unless using adequate contraception.

          -  Patients with Type I or uncontrolled Type II diabetes.

          -  Patients with a history of long time interval between start of Q wave and end of T
             wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart
             rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged

          -  Patients with paroxysmal (e.g. intermittent) atrial fibrillation

          -  Patients who have a clinically significant electrocardiogram (ECG) or laboratory
             abnormality at screening (Visit 2)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00394121 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone propionate/formoterol fumarate
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Ages eligible for study: 12 years and above; genders eligible for study: both; prior
        steroid use: steroid-requiring.

        Inclusion Criteria:

          -  History of asthma for at least 12 months.

          -  Documented use of inhaled corticosteriod for at least 4 weeks prior to Screening Visit
             Demonstrate FEV-1 of 40-80% of predicted normal values at Screening and Baseline
             Visit.

          -  Documented reversibility of 15% within 6 months of Screening Visit or at Screening
             Visit (15% increase from pre-FEV-1 levels following albuterol inhalation).

          -  Symptoms of Asthma during Run-in.

          -  Females of childbearing potential must have a negative urine pregnancy test at
             Screening and Baseline Visits. Females are eligible only if they are not pregnant or
             lactating and are either sterile or using acceptable methods of contraception.

          -  Must otherwise be healthy.

          -  Provide written informed consent. Wishes of minors must be respected.

        Exclusion Criteria:

          -  Life-threatening asthma within past year or during Run-in Period.

          -  History of systemic corticosteroid medication within 3 months before Screening Visit.

          -  History of omalizumab use within the past 6 months.

          -  History of leukotriene receptor antagonist use, e.g., montelukast, within the past
             week.

          -  Current evidence of history of any clinically significant disease or abnormality
             including uncontrolled hypertension, uncontrolled coronary artery disease, congestive
             heart failure, myocardial infarction, or cardiac dysrhythmia.

          -  Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during
             Run-in Period.

          -  Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary
             disease [COPD], cystic fibrosis, bronchiectasis).

          -  Known Human Immunodeficiency Virus (HIV)-positive status.

          -  Smoking history equivalent to "10 pack years".

          -  Current smoking history within 12 months prior to Screening Visit.
Clinical trial NCT00344110 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Age: 20 - 75 years old

          -  Gender: Male or female

          -  Status: Outpatients

          -  Mild to moderate essential hypertension

        Exclusion Criteria:

          -  Pregnant women, lactating mothers, women suspected of being pregnant, or women who
             wish to be pregnant

          -  Patients with msSBP >==180 mmHg and/or msDBP >=110 mmHg at Visit 1, 2 or 3

          -  Patients with or suspected of having secondary hypertension (due to aortic
             coarctation, primary aldosteronism, etc.)

          -  Patients suspected of having malignant hypertension

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00092053 (phase 3, status: completed)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: placebo, ibandronate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria: -postmenopausal for at least 3 years, with osteoporosis at any of the
        following sites: [BMD > 2.0 standard deviations below young normal mean bone mass for the
        hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the
        normative database provided by each individual manufacturer].

          -  willing to take study-supplied calcium and vitamin D supplement (or equivalent) and to
             discontinue any non-study calcium supplements for run-in period and the duration of
             the study. Exclusion Criteria: -pregnant or lactating, or of childbearing potential.

          -  participated in another therapeutic trial with an investigational compound within 30
             days of randomization.

          -  history of hypersensitivity to any component of ibandronate tablets or has hereditary
             problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption.

          -  an abnormality of the esophagus which delays esophageal emptying such as stricture or
             achalasia.

          -  unable to stand or sit upright for at least 60 minutes once a month.

          -  current use of illicit drugs, or history of drug or alcohol abuse within the past five
             years.

          -  has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate or
             severe hypertension which is uncontrolled; new onset angina or myocardial infarction
             within six months of entry into the study; evidence for impaired renal function; organ
             transplantation; or other significant end organ diseases (genitourinary,
             cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).

          -  history of or evidence of metabolic bone disease (other than postmenopausal bone
             loss).

          -  clinical fracture in the past year.

          -  is receiving or has received treatment prior to randomization which might influence
             bone turnover.

          -  is receiving or expected to receive during the course of the study any medication
             (other than study medication) which might alter bone or calcium metabolism, including
             Vitamin A in excess of 10,000 IU per day or Vitamin D in excess of 5000 IU per day,
             calcitonin, phenytoin, heparin, or lithium.
Clinical trial NCT01558271 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, placebo, liraglutide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Participants who have had a diagnosis of type 2 diabetes mellitus before screening.

          -  Participants who have been Oral Antihyperglycemic Medication (OAM)-naïve (diet and
             exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and
             are willing to discontinue this medication. Participants taking OAM monotherapy must
             complete 8-week washout period prior to randomization.

          -  Participants who are OAM naïve with a screening glycosylated hemoglobin (HbA1c) value
             of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM
             monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value
             of 7.0% to 10.0%.

          -  Participants who have a body mass index (BMI) of 18.5 kilograms per meter squared
             (kg/m^2) to 35.0 kg/m^2.

        Exclusion Criteria:

          -  Participants who have a diagnosis of type 1 diabetes.

          -  Participants who have previously been treated with any other glucagon-like peptide-1
             (GLP-1) analog.

          -  Participants who have been receiving more than half of the maximum dose of
             sulfonylureas at screening.

          -  Participants who have been currently taking insulin or TZD, or have had previous
             insulin or TZD treatment within 3 months before screening.

          -  Participants who have obvious clinical signs or symptoms of pancreatitis, a history of
             chronic pancreatitis or acute pancreatitis at screening, as determined by the
             investigator. Participants who have a serum amylase concentration ≥3 times the upper
             limit of the reference range and/or a serum lipase concentration ≥2 times the upper
             limit of the reference range, as determined by the central laboratory at screening.

          -  Participants who have self or family history of medullary C-cell hyperplasia, focal
             hyperplasia, or medullary thyroid carcinoma (MTC).
Clinical trial NCT00257010 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: almotriptan malate
SMILES: CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Have a history of migraine for at least one year

          -  Have an average of 1 - 14 migraines per month for the 6 months prior to study entry

          -  Able to swallow oral medication

          -  Able to complete a headache diary

          -  Only taking one migraine preventive medication and on the same dose of that medication
             for at least 30 days before entering the study)

        Exclusion Criteria:

          -  Have an allergy to almotriptan malate or have stopped taking almotriptan malate due to
             side effects

          -  Have 15 or more days within a month in which you have a headache

          -  Usually experience migraine aura (most common symptoms being visual disturbances or
             tingling sensations before migraine pain begins) without a headache

          -  Experience more than 6 non-migraine headaches per month
Clinical trial NCT00651118 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: placebo, azelastine hcl, azelastinehcl / fluticasone propionate, fluticasone propionate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O, CN1CCCC(CC1)N1N=C(CC2=CC=C(Cl)C=C2)C2=CC=CC=C2C1=O, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients 12 years of age and older with a 2 year history of moderate
             to severe seasonal allergic rhinitis

          -  Must be in generally good health

          -  Must meet minimum symptom requirements, as specified in the protocol

          -  Must be wiling and able to provide informed consent and to participate all study
             procedures

          -  Positive skin test to a prevalent spring allergen

        Exclusion criteria:

          -  On nasal examination,the presence of nasal mucosal erosion, nasal ulceration or nasal
             septal perforation

          -  Nasal disease likely to affect the deposition of the medication or evaluation, such as
             sinus infection, nasal polyps or severe deviated septum

          -  Nasal or sinus surgery within the previous 6 months

          -  Chronic sinus infection (more than 3 per year)

          -  Planned travel outside the study area during the study period

          -  Use of any investigational drug within 30 days of the first visit

          -  Hypersensitivity (bad reaction) to azelastine hydrchloride nasal spray (Astelin), or
             fluticasone propionate nasal spray (Flonase)

          -  Women who are not using an acceptable method or birth control

          -  Women who are pregnant or nursing

          -  Upper respiratory tract infection such as common cold, flu, sinus infection within 2
             weeks of first study visit

          -  Asthma or other lung diseases such as COPD. Mild asthma symptoms may be considered
             after consultation with the investigator

          -  Irregular heartbeat or other symptomatic heart conditions

          -  History of alcohol or drug abuse

          -  History of glaucoma

          -  Use of medications that could affect the study results
Clinical trial NCT00110123 (phase 3, status: terminated)
Conditions: intraocular melanoma, metastatic cancer
ICD codes: Z96.1, T85.22XS, T85.21XS, T85.22XA, T85.22XD, T85.21XA, T85.21XD, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fotemustine, isolated perfusion
SMILES: CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)N=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed liver metastases secondary to uveal melanoma

               -  Surgically incurable or unresectable disease

          -  No detectable extrahepatic metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 2,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL

        Hepatic

          -  Bilirubin < 1.5 times upper limit of normal (ULN)

          -  ALT and AST < 5 times ULN

          -  Alkaline phosphatase < 5 times ULN

          -  Gamma-glutamyltransferase < 5 times ULN

          -  Lactic dehydrogenase < 5 times ULN

        Renal

          -  BUN < 1.5 times ULN

          -  Creatinine ≤ 1.5 times ULN

        Cardiovascular

          -  No uncontrolled angina pectoris

          -  No myocardial infarction within the past 6 months

          -  No uncontrolled high blood pressure

          -  No evolutive intracranial hypertension

          -  No other severe cardiac disease

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active gastroduodenal ulcer

          -  No diabetes

          -  No active or uncontrolled infection

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance and follow-up

          -  No other uncontrolled severe medical condition

          -  No other malignancy within the past 5 years except surgically cured carcinoma in situ
             of the cervix or basal cell or squamous cell skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunologic or biologic therapy

        Chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy for metastatic disease

          -  No concurrent radiotherapy

        Surgery

          -  Recovered from prior major surgery

        Other

          -  No prior antineoplastic drugs for metastatic disease

          -  More than 4 weeks since prior investigational drugs

          -  No other concurrent anticancer agents or therapies
Clinical trial NCT00036400 (phase 3, status: completed)
Conditions: stomach neoplasms, rectal neoplasms
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of gastric cancer or rectal cancer for whom
             the treatment plan is preoperative chemotherapy and radiation therapy, followed by
             surgery

          -  have a life expectancy of greater than 6 months

          -  have a baseline hemoglobin value of >= 10 g/dL and < 15 g/dL and adequate hematologic
             function

          -  have adequate liver and kidney function

          -  if female, must be postmenopausal, surgically sterile, or practicing an effective
             method of birth control.

        Exclusion Criteria:

          -  Rectal cancer patients who have received chemotherapy or gastric cancer patients who
             have received more than two cycles of chemotherapy

          -  anemia due to factors other than cancer or chemotherapy (e.g., iron, vitamin B12 or
             folate deficiencies, hemolysis or gastrointestinal bleeding)

          -  history of any other major medical condition or uncontrolled disease

          -  had a transfusion of white blood cells or packed red blood cells within one month
             prior to study entry or administration of androgen (male sex hormone) therapy within 2
             months of study entry

          -  have received prior treatment with epoetin alfa or any investigational forms of
             erythropoietin within the previous six months.
Clinical trial NCT01286558 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: 40 mg telmisartan, 5 mg amlodipine, 5 mg amlodipine, 80 mg telmisartan
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion criteria:

          1. Essential hypertensive patients

               -  If already taking antihypertensive drugs, mean seated diastolic blood pressure
                  (DBP) must be >=90 and >=114 mmHg

               -  If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114
                  mmHg

          2. Able to stop all current antihypertensive drugs without risk to the patient based on
             the investigators opinion.

        Exclusion criteria:

          1. Patients taking 3 or more antihypertensive drugs at signing the informed consent form

          2. Patients with known or suspected secondary hypertension

          3. Patients with clinically relevant cardiac arrhythmia

          4. Congestive heart failure with New York Heart Association (NYHA) functional class
             III-IV

          5. Patients with recent cardiovascular events

          6. Patients with a history of stroke or transient ischaemic attack within last 6 months
             before signing the informed consent form

          7. Patients with a history of sudden deterioration of renal function with angiotensin II
             receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or
             patients with post-renal transplant or post-nephrectomy

          8. Patients who have previously experienced characteristic symptoms of angioedema (such
             as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment
             with ARBs or ACE inhibitors

          9. Patients with known hypersensitivity to any component of the investigational product,
             or a known hypersensitivity to dihydropyridine-derived drugs

         10. Patients with hepatic and/or renal dysfunction

         11. Pre-menopausal women who are nursing or pregnant
Clinical trial NCT00163293 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: ciclesonide, placebo
SMILES: [H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Outpatients

          -  Symptoms consistent with the diagnosis of asthma for at least 12 months

          -  Forced Expiratory Volume in one Second (FEV) at least 80% of predicted

          -  Participants who have a history of reversible airway obstruction

          -  Good health with the exception of asthma

        Main Exclusion Criteria:

          -  History of life-threatening asthma

          -  A hospitalization for asthma within the last 3 months, or more than two
             hospitalizations for asthma within the last year

          -  Concomitant severe diseases or diseases which are contraindications for the use of
             inhaled steroids

          -  Participants suffering from relevant lung diseases causing alternating impairment in
             lung function (e.g. chronic bronchitis or emphysema)

          -  Prematurely born children (<36 weeks of gestation)

          -  Smokers

          -  Pregnancy (or intention to become pregnant during the course of the trial), breast
             feeding or lack of safe contraception by female of child-bearing potential